IPOS photocopied

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 38/44, 48/00

A1

(11) International Publication Number: WO 98/41231

(43) International Publication Date: 24 September 1998 (24.09.98)

(21) International Application Number: PCT/CA98/00242

(22) International Filing Date: 18 March 1998 (18.03.98)

(30) Priority Data:

60/040,837	19 March 1997 (19.03.97)	US
60/060,669	2 October 1997 (02.10.97)	US

(71) Applicant *(for all designated States except US)*: GENESENSE TECHNOLOGIES, INC. [CA/CA]; 100 Olivia Street, Winnipeg, Manitoba R3E 0V9 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WRIGHT, Jim, A. [CA/CA]; 15 Bryn Mawr Road, Winnipeg, Manitoba R3T 3K8 (CA). YOUNG, Aiping, H. [CA/CA]; 717 Pacific Avenue, Winnipeg, Manitoba R3E 1G1 (CA).

(74) Agents: COLLARD, Christine, J. et al.; Scott & Aylen, 1000–60 Queen Street, Ottawa, Ontario K1P 5Y7 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SUPPRESSION OF MALIGNANCY UTILIZING RIBONUCLEOTIDE REDUCTASE R1

(57) Abstract

The present invention provides a method of modulating the malignant properties of a cell in a human or other mammal by contacting a neoplastic cell with a growth modulating amount of an expressible nucleic acid sequence for ribonucleotide reductase R1 of the mammal. The present invention also provides and uses a growth modulating amount of the ribonucleotide reductase R1 protein or biologically active peptide to modulate the malignant properties of a cell in a human or other mammal. The method provides for a generally elevated expression of the R1 component of mammalian ribonucleotide reductase. The expressible nucleic acid sequence can be in the form of a vector for gene therapy.